Open Access<p>Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report</p>
Author(s) -
Sungho Yun,
Hui Li,
Hongjuan Shang,
Jun Chen,
Xiaoxing Su,
Wei Le,
Lei Yan,
Liming Tao,
Cailiang Zou,
Wendy Wu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s270961
Subject(s) - crizotinib , ros1 , adenocarcinoma , medicine , sanger sequencing , lung cancer , cancer research , cabozantinib , fusion gene , pathology , cancer , oncology , dna sequencing , biology , gene , genetics , malignant pleural effusion
ROS1 fusions have been identified in 1-2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to 20.0 months for crizotinib treatment in ROS1-rearranged NSCLC. Here, we reported a 45-year-old female diagnosed with stage IVB lung adenocarcinoma with multiple lymph nodes and bone metastasis carrying a novel MPRIP-ROS1 fusion, which was identified by RNA-based NGS (next-generation sequencing) and was sensitive to crizotinib treatment.